Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Autolus Therapeutics Plc ADR (NQ: AUTL ) 4.500 -0.030 (-0.66%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Autolus Therapeutics Plc ADR < Previous 1 2 3 Next > Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress August 03, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer July 19, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023 July 18, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia July 06, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces publication in Cancer Immunology Research June 27, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director June 20, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma June 16, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023 June 06, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO June 02, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL May 22, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA May 12, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress May 04, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO April 27, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner April 27, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids April 26, 2023 - Expanding the Autolus toolkit of T-cell engineering modules against complex and immunologically hostile cancers, including solid cancer applications From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting April 26, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Host Virtual Capital Markets Day April 25, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023 April 20, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Publication in Molecular Therapy April 04, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces resignation of Chief Financial Officer March 14, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Has No Business Relationship with Silicon Valley Bank March 13, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress March 07, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023 February 15, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces Board changes January 20, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease January 09, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs December 21, 2022 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022 December 12, 2022 From Autolus Therapeutics plc Via GlobeNewswire Autolus Announces Pricing of Public Offering December 08, 2022 From Autolus Therapeutics plc Via GlobeNewswire Autolus Announces Proposed Public Offering in the United States December 08, 2022 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences December 08, 2022 From Autolus Therapeutics plc Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.